Search Results

Slidesets
Industry Supported Symposium: People First Language - Why it Matters
Presented at:
International Workshop on HIV & Women 2024
Abstracts
K156N integrase substitution in combination with 3’PPT resistance mutations against dolutegravir
R. Gruters Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
S-MART: Supporting Self-Management in Adolescents to be Resilient and Thrive.
T. Crowley. Reviews in Antiviral Therapy & Infectious Diseases 9, 2021
Presented at:
International Workshop on HIV & Adolescence 2021
Abstracts
HCV elimination in France. The countdown has started
V. de Ledinghen  Reviews in Antiviral Therapy & Infectious Diseases 11, 2020
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2020
Abstracts
Contact tracing to engage hard to reach injection networks and achieve micro-elimination: description of the ‘source patient indentification and group overlap treatment’ (spigot) pilot program
B. Eckhardt  Reviews in Antiviral Therapy & Infectious Diseases 11, 2020
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2020
Abstracts
Reasons why parents are reluctant to disclose their HIV positive status to their children: Lesson Learnt in Botswana
M. Mokalake Reviews in Antiviral Therapy & Infectious Diseases 10, 2020
Presented at:
INTEREST 2020
Abstracts
Improving access to optimal treatment: the role of the community as a catalyst for Dolutegravir scale-up in Senegal
B. Ibrahima Reviews in Antiviral Therapy & Infectious Diseases 10, 2020
Presented at:
INTEREST 2020